Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abbott has released interim data from a 54-week open-label, multi-site efficacy and safety Phase II trial evaluating its experimental treatment levodopa-carbidopa intestinal gel (LCIG) in patients who are suffering from advanced Parkinson's disease.
Subscribe to our email newsletter
The 12 weeks data showed positive results demonstrating an increase in ‘on’ time and decrease in ‘off’ time without troublesome dyskinesias.
Abbott said the primary efficacy endpoint is change from baseline to endpoint in ‘off’ time at 54 weeks.
At 12 weeks, patients reported an average of 3.9 fewer hours of ‘off’ time and 4.6 additional hours of ‘on’ time without troublesome dyskinesias.
University of Cincinnati Neuroscience Institute Neurology assistant professor and lead investigator of the study Alberto Espay said with advanced Parkinson’s disease, the goal of treatment is to provide patients with as much ‘on’ time as possible, while limiting the troublesome dyskinesias they may experience.
"The interim data from this study of LCIG show clinically meaningful improvements in these important measures," Espay said.